Skip to main content
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. — Investor Relations & Filings

Ticker · TYRA ISIN · US90240B1061 US Professional, scientific and technical activities
Filings indexed 366 across all filing types
Latest filing 2026-04-17 Annual Report
Country US United States of America
Listing US TYRA

About Tyra Biosciences, Inc.

https://tyra.bio/

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company specializes in therapies targeting fibroblast growth factor receptor (FGFR) biology, aiming to overcome tumor resistance and address key drivers of disease. Utilizing its proprietary SNÅP Discovery Engine, Tyra Biosciences designs innovative molecular structures. Its lead clinical program involves the development of oral dabogratinib for the treatment of skeletal dysplasia and urologic cancers.

Recent filings

Filing Released Lang Actions
ARS - Tyra Biosciences, Inc. (0001863127) (Filer)
Annual Report
2026-04-17 English
DEF 14A - Tyra Biosciences, Inc. (0001863127) (Filer)
Proxy Solicitation & Information Statement
2026-04-17 English
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
Regulatory Filings
2026-04-17 English
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
Regulatory Filings
2026-04-02 English
144 - Tyra Biosciences, Inc. (0001863127) (Subject)
Regulatory Filings
2026-03-25 English
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
Director's Dealing
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.